DiseasesStudies updated this monthBlood pressure pills — do they treat the cause or just the measurement result?
What do Natural Therapy Specialists write?
Blood pressure measurement is used to assess a patient’s condition, and an upper-arm measurement is indicated as the correct method.
The medicines used block angiotensin receptors in blood vessels, while the author identifies a higher level of regulation as the place where a therapeutic effect should be achieved.
In the author’s view, restoring impaired autoregulation could reverse some changes and reduce the need for medication.
Prof. Klaus F. Kopp claims that typical medicines block hormones linked to high blood pressure but do not treat the bicarbonate deficiency he describes.
Prof. Klaus F. Kopp presents bicarbonate deficiency as an unresolved cause and bicarbonate replacement as a way to treat hypertension.
What does scientific research from PubMed · Europe PMC say?
We selected 4 studies with the best, positive results. This is a selection, not a full review of all research.
Total number of studies on this topic in PubMed: 43 040.
Aim of the study: To summarize recent evidence on the effectiveness and safety of antihypertensive fixed-dose combination (FDC) medications, and to describe the facilitators and barriers to implementing FDCs in US clinical practice.
Results: Recent clinical practice guidelines include the use of FDCs to treat high blood pressure. Clinical trials in recent years support the use of antihypertensive FDCs, including low-dose triple- and quadruple-therapy FDCs. Starting treatment with a low-to-standard-dose dual-therapy FDC resulted in better blood pressure control than starting with standard-dose monotherapy, and triple-therapy FDCs produced better blood pressure control rates than dual-therapy FDCs. Retrospective cohort studies showed that FDCs are associated with better medication adherence, less clinical inertia, shorter time to blood pressure control, and improved cardiovascular outcomes. We also discussed barriers and factors that support wider implementation of antihypertensive FDCs in clinical practice. FDC treatment for hypertension is not commonly used, despite historical and recent data supporting its effectiveness, safety, and benefits.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Valsartan/hydrochlorothiazide is a combination of an angiotensin II receptor antagonist and a diuretic, indicated for patients with hypertension as initial therapy and for those whose condition is not controlled with monotherapy. The aim was to evaluate the pharmacokinetic, pharmacodynamic, and clinical effectiveness of valsartan/hydrochlorothiazide in treating hypertension and its effects on other cardiovascular outcomes.
Results: Valsartan/hydrochlorothiazide has been shown to be superior to its individual components in randomized controlled studies of patients with moderate-to-severe hypertension and in patients who did not respond to monotherapy. Compared with amlodipine, valsartan/hydrochlorothiazide had a similar rate of the combined outcome of morbidity and mortality. Valsartan/hydrochlorothiazide has also been studied in specific patient groups, such as people with diabetes, people with obesity, older adults, Black people with hypertension, and people with hypertension and additional cardiovascular risk factors; it has been shown to be effective in these groups. Valsartan/hydrochlorothiazide has been shown to be an effective fixed-dose combination antihypertensive medicine that is well tolerated and has few side effects.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Congenital adrenal hyperplasia (CAH) due to 17α-hydroxylase/17,20-lyase deficiency (17OHD) is a rare form of CAH characterized by cortisol deficiency, impaired sex steroid production, and excess deoxycorticosterone (DOC), resulting in low-renin hypertension and hypokalemia.
Results: Despite treatment escalation, DOC and pregnenolone levels remained elevated and blood pressure remained poorly controlled. After crinecerfont 100 mg twice daily was started, blood pressure improved to 120-130/80-90 mmHg, plasma renin activity increased, and DOC and pregnenolone concentrations returned to normal without any further increase in glucocorticoids. Clinical and biochemical improvements were sustained during 12 months of follow-up. This case is the first reported use of crinecerfont in 17OHD and suggests that CRF1 receptor antagonism may offer a new treatment option for treatment-resistant hypertension driven by ACTH-dependent mineralocorticoid excess.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Blood pressure (BP) control among people with hypertension remains inadequate. This study aims to assess achievement of BP targets among people prescribed antihypertensive medicines, examine medication nonadherence, and identify demographic factors associated with achieving targets and with medication nonadherence in this population.
Results: Antihypertensive medicines were prescribed to 567 participants. Based on imputed data, 63.8% of these participants achieved the 2013 BP target. The mean medication nonadherence score was 1.6 (SE ± 0.06), with 34.8% of participants being nonadherent. Taking multiple antihypertensive pills was associated with a lower likelihood of achieving BP targets. In the sensitivity analysis, 38.4% achieved the 2024 BP target, and in the multivariable analysis, being overweight or obese was associated with not achieving the 2024 targets. The study highlights the gap between BP targets in guidelines and achievement of these targets in real-world practice. It identified key patient and medication factors that could guide efforts to improve BP target achievement. Trial Registration: ClinicalTrials.gov identifier: NCT03191227.
“Not stated” does not mean nobody paid — the database does not always record it.
What do orthomolecular medicine doctors write?
Sources (11)
- Jerzy Jaśkowski — Podstawy fizyczne hemodynamiki cz. 2
- Andrzej Frydrychowski — Aurikuloterapia - refleksoterapia uszu cz. 2
- Prof. Klaus F. Kopp — The Bicarbonate-Deficiency-Syndrome (BDS): Professor Dr. med. Klaus F. Kopp
- Prof. Klaus F. Kopp — Das Bikarbonat-Mangel-Syndrom (BDS): Professor Dr. med. Klaus F. Kopp
- Fixed-Dose Combination Medications for Treating Hypertension: A Review of Effectiveness, Safety, and Challenges. · Curr Hypertens Rep 2020
- Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy. · Expert Opin Drug Metab Toxicol 2009
- Successful hypertension control in 17-hydroxylase deficiency using crinecerfont. · JCEM Case Rep 2026
- Prescribing, Medication Adherence, and Blood Pressure Goal Achievement Among Middle-to-Older Age Adults in a Primary Care Setting. · Int J Hypertens 2026
- Orthomolecular Medicine News Service — Top Twelve Vitamin D Papers for 2017
- Orthomolecular Medicine News Service — Heart Failure or Therapy Failure? Toxins Cause Cardiomyopathy
- Orthomolecular Medicine News Service — Magnesium Decreases Hyperactivity in ADHD Children
Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.